Peptide Stack
GLOW Stack (GHK-Cu + BPC-157 + TB-500)
Aesthetic-leaning upgrade to the Wolverine Stack, adding GHK-Cu for skin and collagen. Three-peptide blend with zero combination data and no injectable GHK-Cu human evidence.
Summary Does the GLOW Stack help skin or injuries, and is it safe? Show / hide ↓
The GLOW Stack is one injectable vial containing three peptides, which are small chains of amino acids: GHK-Cu, BPC-157, and TB-500. It usually contains 70 mg total, including 50 mg of GHK-Cu, a copper-containing peptide linked to skin and collagen support. Human studies found that creams with GHK-Cu improved skin thickness, density, and wrinkle depth, but there are no human studies of injected GHK-Cu, BPC-157, TB-500, or this combination. Possible concerns include copper overload, injection-site reactions, blue-green skin discoloration, and unknown stability when all three are mixed together.
What this means for you: This stack has weak evidence, especially for injections and injury repair. There is not enough human research to justify buying it, and its safety limits are unknown.
weak evidenceThe GLOW Stack combines GHK-Cu (copper tripeptide-1) with BPC-157 and TB-500 in a single lyophilized vial, typically 70 mg total in a 5:1:1 mass ratio (50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157). Priced around $128, it is positioned as an aesthetic-leaning upgrade to the Wolverine stack.
GHK-Cu has the best human evidence of the three components, but only for topical use. Controlled trials show increased skin density and thickness and reduced wrinkle depth from facial creams. There are no human PK or RCT data for injectable GHK-Cu at all, and injecting 50 mg is far outside anything studied.
The stack is mechanistically layered: GHK-Cu for collagen and gene expression, BPC-157 anti-inflammatory, TB-500 for cell migration. No published study has ever evaluated the three-peptide combination together. Synergy claims are entirely extrapolated from single-compound literature.
GHK-Cu dominates by mass (50 of 70 mg), so users chasing injury repair get comparatively little BPC-157 or TB-500. Copper overload is the distinctive risk of high-dose systemic GHK-Cu. No human dosing ceiling has been established. Injection-site irritation and blue-green discoloration are commonly reported with copper peptides.
Co-formulation stability of a copper complex alongside two other peptides in one vial is not well characterized. None of the three is FDA-approved for systemic human use.
- Peptides
- GHK-Cu, BPC-157, TB-500
- Typical format
- Single lyophilized vial, 70 mg total in 5:1:1 ratio (50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157). Around $128.
- Marketed for
- Skin quality, collagen density, anti-aging appearance, hair, plus general tissue repair
What works
- GHK-Cu has the best human evidence of the three (topical only: increased skin density, reduced wrinkle depth)
- Mechanistically layered across three distinct pathways
- Single-vial convenience for a three-compound protocol
What to watch for
- No published study has evaluated the three-peptide combination together
- Strong GHK-Cu data is topical only. No human data for injectable GHK-Cu at any dose
- GHK-Cu dominates by mass, so users get little BPC-157/TB-500 for injury repair
- Copper overload risk with no established human dosing ceiling
Copper overload is the distinctive risk. Injection-site irritation and blue-green discoloration commonly reported. Co-formulation stability of copper complex alongside other peptides is not well characterized. None of the three is FDA-approved for systemic human use.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.
- GHK-Cu skin regeneration review (PMC) PubMed
- CuHeal topical GHK-Cu trial (ClinicalTrials.gov) ClinicalTrials.gov
- PCAC backs 6 peptides (AJMC 2026) AJMC